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ABSTRACT 
Cardiovascular disease (CVD) is on the rise in the US and is the leading cause of death 
worldwide [1]. Associated disorders including stenosis of the vasculature and formation 
of atherosclerotic plaques can necessitate the need for repair or replacement. Tissue 
engineering, based on stem cells and scaffolds, is an emerging strategy for the treatment 
of vascular diseases. Patients who typically require vascular replacement often have 
comorbidities such as diabetes and hypertension. There remains the challenge of 
understanding the fate of tissue engineered vascular grafts (TEVGs) in a harsh diabetic 
environment. 
In these experiments we aimed to develop an in-vitro vascular bioreactor model to 1) 
condition our tissue engineered vascular grafts and 2) model both a hyperglycemic and 
hypertensive environment. Our goal was to illicit an appropriate response from the 
vascular grafts caused by exposure to these pathologic environments to better inform us 
regarding the fate of our grafts before requiring an in-vivo model. 
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CHAPTER ONE: INTRODUCTION AND BACKGROUND 
1.1 The Impact of Cardiovascular Disease 
In the United States, cardiovascular disease (CVD) is on the rise. In 2017, the American 
Heart Association reported CVD as the underlying cause of 801,000 deaths in the US, in 
other words, every 1 in 3 deaths [2]. CVD includes stroke, atherosclerosis, congenital 
heart disease, coronary artery disease and peripheral artery disease. Of specific interest, 
peripheral artery disease (PAD), refers to partial or complete obstruction of arteries. PAD 
is usually caused by atherosclerosis and the most common symptom of PAD is 
intermittent claudication. Patients with diabetes are among those most likely to develop 
PAD and if left untreated, critical limb ischemia (CLI) can develop and lead to ulceration 
and in extreme cases amputation [3,4].  
1.2 Anatomy and Physiology 
The vascular system consists of blood vessels working to carry blood to and from the 
heart. Within this system, both arteries and veins have three distinct tissue layers; the 
tunica externa, tunica media, and tunica intima. The tunica intima, the innermost layer, is 
comprised of the endothelium and the sub endothelial layer [5].  The endothelium, a 
continuous layer of endothelial cells, lines the vessel and acts as a permeable barrier 
between the vessel wall and blood, working to regulate the transport of fluid, protein and 
cells into and out of tissues [6]. Beneath this layer, the sub endothelial layer acts to bind 
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the endothelium to the connective tissue. The structure of this tunic allows for specific 
functionality in regulating circulatory function within the vascular system. Moving 
outwards from the tunica intima, the tunica media surrounds the intima separated only by 
the internal elastic lamina. This layer is primarily composed of layers of vascular smooth 
muscle cells. In muscular arteries, as compared to elastic arteries, this layer is typically 
thicker whereas the media in a vein would typically be thinner and less pronounced. The 
outermost layer, separated by the external elastic lamina, is comprised of areolar 
connective tissue with residential fibroblasts as well as vascular smooth muscle cells [7]. 
1.3 Vascular Disease Pathology  
Vascular diseases are characterized by the narrowing or complete obstruction of the 
vessel lumen. Gradual weakening of the vessel walls can lead to dilation or rupture. A 
major mechanism contributing to this is arteriosclerosis, literally meaning “hardening of 
the arteries”. Arteriosclerosis has three major patterns; a) arteriolosclerosis referring to 
the thickening of small arteries and arterioles, b) medial calcific sclerosis, which is 
typically age related and not involving the lumen and c) atherosclerosis, the development 
of lipid based fatty plaques [8]. The progression of atherosclerosis, arguably the most 
important factor, is characterized by a “response-to-injury” hypothesis in which the 
arterial walls respond to chronic inflammation initiated by damage to the endothelium 
[9]. 
 
 
 
 
 
&!
Chronic endothelium injury begins subtly, usually due to associated CVD risk factors. 
These can include smoking, hypertension, and hyperlipidemia which can lead to altered 
hemodynamics. This injury marks the beginning of the activation of the endothelium, a 
phase characterized by increased permeability, leukocyte adhesion, greater thrombotic 
!"#$%&'()'*+,-./&0"1&2'34&0,-50&6.-6758$%+9'2":#%:;'
Schematic diagram of hypothetical “Response-to-Injury” sequence of 
events leading to the development of atherosclerosis. [8] 
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potential as well as the adhesion of blood monocytes to the endothelium. Once adhered, 
the monocytes and other leukocytes begin to migrate into the intima and transform into 
macrophages and foam cells. Macrophages engulf lipoproteins, specifically the low 
density lipoproteins (LDL), as well as secrete IL-1 and tumor necrosis factor (TNF) that 
increases leukocyte adhesion. As the endothelium is increasingly damaged, platelets 
begin adhering to the endothelium and become activated. Smooth muscle cells respond to 
the release of factors and activation of the platelets and begin migrating from the media 
towards the intima. Proliferation of the SMCs leads to increased deposition of 
extracellular matrix resulting in the formation of an atherosclerotic plaque [8]. At this 
stage there are key functional consequences; atherosclerotic formation weakens the 
arterial walls which can lead to a bulging of the walls. Overtime this can result in the 
formation of an aneurysm which puts the patient at risk of rupture. Clinically silent 
plaques on the wall, termed “stable”, become an issue only when disrupted, thus 
becoming “vulnerable” [10]. The dislodgement of the plaque can result in ischemia, 
stroke or myocardial infarction dependent upon the final resting location [11]. 
1.3.1 Carotid Artery Pathology 
The carotid artery is a major artery plagued by atherosclerotic formation and blockage of 
this artery is a leading cause of stroke and resulting death [12]. The carotid bifurcation, a 
region where blood flow divides and fluid velocity patterns are more complex, is a 
common location of atherosclerotic formation, thus suggesting the geometry of the vessel 
as well as the fluid dynamics plays a key role in inciting formation [13]. In large arteries 
and areas away from major bifurcations the typical wall shear stress (WSS) experienced 
(!
ranges from 20 to 40 dyn/cm2. However, in regions where flow is disturbed or flow is 
separated, shear stresses can be zero in the separation region and as high as 50 dyn/cm2 in 
the surrounding area. [11] 
 
 
Endothelial cells, as mentioned previously, are highly responsive to changes in blood 
flow and react accordingly to regulate vasomotion. It is hypothesized that as a result of 
these low WSS experienced, endothelial cells undergo a change in morphology as well as 
potentially increase the permeability of the vessel leading to a region more susceptible to 
atherosclerotic formation [13]. 
 
!"#$%&'>)'?:%-."2'@%.&%+'A"B$%C:."-5'
Effect of geometry of carotid artery bifurcation on resulting shear stresses 
within the vessel leading to formation of atherosclerotic plaque [13]. 
)!
1.4! Impact of Diabetes in Cardiovascular Disease
Diabetes Mellitus (DM), characterized by insulin resistance or lack thereof is a huge 
contributor to the progression of vascular disease. There are three main classes of DM: 
Type 1, Type 2 and gestational. Type 1 Diabetes results from insufficient production of 
insulin due to an autoimmune response that destroys the pancreatic beta cells. Type 2 
Diabetes, the more common form is characterized by a resistance to insulin and accounts 
for 90-95% of cases worldwide [14]. Patients with DM are ten times more at risk for 
developing a CVD in their lifetime. A key factor contributing to this is the diabetes-
associated accelerated atherosclerosis. Although the underlying mechanisms are not 
completely understood, there are many key contributing factors that play a role in the 
progression of atherosclerosis and CVD as shown in the figure below [15]. 
!"#$%&'=)'E%-#%&00"-5'-B'@./&%-0CF&%-0"0':52'?:%2"-G:0C$F:%'H"0&:0&'
Overview of progression of risk factors leading to atherosclerosis and 
cardiovascular disease [15]. 
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1.4.1 Endothelial Dysfunction 
Endothelial dysfunction refers to the activation of endothelial cells, representing a switch 
from a quiescent phenotype to an activated defense response from the host [16]. Most 
cardiovascular risk factors are associated with an increase in reactive oxygen species 
(ROS) which leads to oxidative stress of the endothelium [15]. Production of ROS such 
as H2O2 and prolonged exposure to them can induce senescence of the ECs leading to 
loss of integrity as well as detachment. Increase of ROS is also responsible for 
aggravating inflammation of the vasculature, which further promotes leukocyte 
adherence and migration. Monocytes are also increasingly recruited and begin to switch 
phenotypes to transform into foam cells. These issues lead to greater damage to the 
endothelium and provide a basis for developing atherosclerosis and other cardiovascular 
diseases as shown in Fig.3 [15]. 
1.4.2 Hyperglycemia 
Type 2 diabetes is characterized by insufficient production of insulin to counter target 
organ insulin resistance. Inability of the body to maintain appropriate glucose levels leads 
to elevated blood glucose levels referred to as hyperglycemia [17]. Vascular injury and 
increased inflammation are devastating responses to the increase in glucose levels. 
Hyperglycemia enhances the expression of inflammatory genes to promote the attraction 
and adhesion of monocytes seen in the early stages of atherosclerosis [14]. It is the 
dysfunction at a cellular level that is believed to elicit such a detrimental response. An 
inevitable trait of hyperglycemia is the production of advanced glycation end products 
(AGEs). AGE production is normal as aging occurs, however the accumulation of AGEs 
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is rapidly accelerated in diabetes [18]. High glucose levels lead to increased production of 
reactive oxidation species (ROS). The typical response to the presence of ROS is the 
production of antioxidant enzymes but in diabetic conditions this is not always the case 
[19]. This response coupled together with the imbalance of ROS production results in 
oxidative stress [19]. It is thought that this oxidative stress in the endoplasmic reticulum 
leads to an impairment of b-cells function and increased ROS formation [17]. 
 
1.4.3 Hypertension 
Hypertension is highly prevalent worldwide and common in patients with diabetes. The 
incidence of hypertension increases in populations with cardiovascular co-morbidities 
such as diabetes mellitus, and peripheral artery disease [20]. Hypertension is highly 
correlated with obesity in patients and is linked through mechanisms such as metabolic 
and vascular dysfunction [21]. Of major note is the role vascular remodeling plays in 
increased arterial stiffening. This remodeling is characterized by a change in the normal 
structure of blood vessels to accommodate physical or chemical changes in the 
environment. Arterial stiffening, although typically associated with increasing age, is 
found in hypertension as remodeling allows the vessels to withstand higher pressures 
[22]. This stiffening, caused by the changes in extracellular matrix is well known to 
increase total peripheral resistance [23]. The major components in the arterial wall are 
collagen and elastin. Elastin, the dominant protein, allows elastic recoil of the arteries 
while collagen provides strength to the arterial wall [24]. Elastin is primarily produced 
during development. As elastin fibers are degraded over time or through tissue damage, 
production of collagen, a much stiffer protein, is increased. Collagen is 100-1000 times 
	 9	
stiffer than elastin and takes on a greater mechanical load as the elastin degrades [23]. 
Calcification of the elastic lamellae contributes to increased stiffening. [XU] Current 
treatment options for hypertension includes prevention of CVD by strict control of blood 
glucose levels, weight reduction, limiting alcohol intake and to reduce smoking [19]. 
Recommended target blood pressures for diabetic patients are below 130/80 mmHG [19]. 
1.5 Management of Diabetes 
Approximately 20 million people are affected by diabetes mellitus (DM) in the U.S. [25].  
There currently remains no cure for diabetes. Instead, a strict management and regulation 
of blood glucose level has been shown to be an effective method in reducing 
microvascular disease, however it has not been shown to reduce myocardial infarction or 
vascular disease on a macro level [26,27]. Self-monitoring of glucose with the use of 
blood glucose pumps along with proper insulin administration is essential to an effective 
treatment [26]. For patients with type 1 DM, treatment includes insulin injections 
combined with an increase in exercise and diet control. Initial therapy for patients with 
type 2 DM includes reduction of weight and an increase in physical activity [26].  
 
1.6 Current Engineering Solutions 
As diabetes- induced atherosclerotic and calcification leads to greater obstruction, the risk 
of critical limb ischemia (CLI) increases [28]. This disease, if left untreated, can 
ultimately lead to limb loss. It is estimated that CLI leads to 35% of major amputations 
yearly and diabetic patients are 10 times more likely to undergo an amputation [29]. 
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Typically surgical bypass grafting and endovascular treatments are employed as a first 
approach to reduce the need for amputation [30]. Vascular stents are metal frameworks 
that act to support the lumen of the vasculature from within. Bare metal stents (BMS) are 
typically comprised of nitinol, a material that self-expands at physiological temperatures. 
[ add reference for nitinol]. Combined with balloon angioplasty, stents act to prevent 
restenosis from occurring. However, stenting inflicts trauma to the lumen of the vessels 
which can lead to thrombosis and intimal hyperplasia leading to restenosis of the stent. 
As an improvement, drug eluting stents (DES) were designed to further prevent 
restenosis by eluting drugs such as Sirolimus and Paclitaxel, which have been shown to 
improve the outcome of coronary procedures. However, the anti-proliferation properties 
of these drugs lead to decreased healing of the endothelium after trauma. [add reference] 
Advances in the last decade have shifted the open surgery grafting approach to a 
percutaneous endovascular treatment associated with lower morbidity. The continuous 
development and improvement of vascular stents has greatly improved the outcome of 
these percutaneous procedures [29]. However, in recent studies it has been shown that for 
a diabetic population, coronary artery bypass grafting (CABG) is the preferred 
revascularization procedure [26]. Due to the systemic effect of the vascular disease, many 
patients do not have viable homologous donor arteries. In these cases, synthetic materials 
are turned to as alternative. There are many approaches to provide treatment for the 
degradation of the vasculature. Some of these treatments include the use of autologous 
grafts and synthetic grafts as replacements. Although these practices are commonly used, 
they do have their limitations and complications. Current synthetic graft approaches 
$$!
include the use of polytetrafluoroethylene (PTFE) based vascular grafts such as Gore-
TexTM as well as using Dacron and other polymeric materials. These approaches are 
limited by their inability to grow with the patient as well as limitation due to higher levels 
of thrombotic complications in the smaller diameter models [31,32].  
!"#$%&'J)'@F.&%5:."G&'K:0C$F:%'L%:B.'
?$%%&5.'0+5./&."C'G:0C$F:%'#%:B.'-5'./&';:%T&.'C-;,%"0&2'-B'&EM!N'UL-%&V'E%-,:.&5V'
K:0C$F:%'L%:B.W' '
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CHAPTER TWO: VASCULAR TISSUE ENGINEERING 
2.1 Vascular Tissue Engineering 
Tissue engineering is a rapidly emerging field in vascular therapies. The inadequacy of 
the aforementioned treatments, the large rate of revision surgeries as well as a lack of 
autologous vessel sources in a large proportion of the patients has spurred the search for a 
solution [33]. There is a growing need for a functional replacement capable of 
regeneration. To be considered a functional tissue engineered vascular graft (TEVG), the 
graft should be non-thrombogenic, non-immunogenic and exhibit good mechanical 
strength as well as vasoreactivity. The specific tri-layer design should be maintained 
ideally down to the cellular level with residential fibroblasts and smooth muscle cells as 
well as a continuous endothelial cell lining the intima [33,34]. 
 
2.1.1  Paradigm 
The general scaffold-based top down approach begins first with the isolation of a suitable 
cell source from the patient. These cells are seeded onto a biodegradable scaffold. 
Following this, the new graft will be conditioned in vitro before implanting back into the 
original patient as depicted in the figure below [34]. 
 
 
 
$&!
 
 
2.2! Biologic Scaffolds 
The biomaterials used in cardiovascular tissue engineering should be biocompatible and 
of adequate mechanical strength to withstand stresses [34]. Vascular grafts based on 
natural polymers, primarily elastin, collagen and fibronectin, are typically biocompatible 
and are better suited for optimal cell attachment and signaling as compared to synthetic 
materials [33,34]. Decellularized tissues are of particular interest because of their wide 
availability, ECM-composition and mechanical strength-retaining structure. Tissues may 
!"#$%&'D)'K:0C$F:%'M"00$&'N5#"5&&%"5#''
Paradigm of general approach to producing a patient-tailored vascular graft  [34]. 
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be derived from allogeneic or xenogeneic sources and decellularization achieved by 
washing the tissues with detergents and buffers [33]. Because these scaffolds are derived 
from natural materials, degradation of the tissue does not result in harmful products. In 
fact, the rapid degradation and ability for replacement is an important attribute of ECM-
based scaffold leading to constructive remodeling of the tissues [35].  
 
2.3 Cell Populations and Seeding 
There are many options available for a suitable cell population to revitalize the chosen 
scaffold. An ideal source needs to be non-immunogenic, easily harvestable, of 
proliferative nature and possess the ability to differentiate into specified cells [36]. Cells 
may be allogeneic, xenogeneic or of an autologous source. Autologous cells, the 
preferable choice, eliminate the risk for immunorejection. However, they may be limited 
in availability, costly to expand, or have minimal proliferative abilities. Popular sources 
for stem cells include bone-marrow-derived stem cells, endothelial progenitor stem cells, 
cardiac stem cells and adipose-derived. Adipose tissue is an ideal source for harvesting 
autologous stem cells. The harvesting from common adipose deposits results in minimal 
pain to the patient and yields clinically significant amounts of cells [37]. These cells have 
been shown to possess high proliferative properties and the ability to differentiate into 
many vascular cell lineages such as endothelial cells, smooth muscle cells and fibroblasts. 
Miranville et al. 2004 demonstrated the ability of Adipose-derived stem cells (ASCs) to 
differentiate into endothelial cells with the addition of growth factors into the culture 
media growth media. Vascular endothelial growth factor (VEGF) (0.5 ng/ml) and insulin-
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like growth factor (IGF) (20ng/ml) promoted the appearance of markers vWF and CD-31 
[38]. Wang et al. 2010 induced differentiation of ASCs with administration of 
transforming growth factor-β1 (TGF-β1) and bone morphogenetic protein-4 (BMP4) 
expression of SMC-related markers α-SMA and SM myosin heavy chain were observed 
[39]. ASCs high plasticity makes them highly desirable for repopulating a vascular graft. 
With the aid of mechanical and chemical cues, there is hope for remodeling and 
regeneration. With an appropriate cell source, there still remains the challenge of 
repopulating the scaffold with the cells as well as ensuring adequate protection from 
subsequent pressures and flows following implantation. Fibrin hydrogels have been 
investigated as a delivery vessel for cells. Because fibrinogen and thrombin, products of 
the coagulation cascade, polymerize to form the fibrin gel, this method is promising as 
the fibrin gel would be biocompatible. Hydrogels have been used to encapsulate cells and 
provide protection during seeding [40]. The fibrin gel acts to provide efficient application 
and even cell distribution. 
 
2.4 In-vitro Bioreactor Graft Conditioning 
Continuing with the general approach of tissue engineering, after combining the cell 
source with the scaffold, a bioreactor is a necessary step, owing to the limitations of static 
culture.  At the time of implantation, the graft should be mechanically strong, exhibit 
vasoreactivity and non-thrombogenecity [33]. Vessel reactors are specifically designed to 
mature and condition the constructs by mimicking the physiological conditions and 
stimuli the native vessel would experience.  
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2.4.1 Mechanical and Biochemical Cues  
Bioreactors subject grafts to forces such as pressure, cyclic strain and wall shear stresses 
to provide necessary cues. The constant cyclic strain induces a more mechanically stable 
scaffold. This strain is important for conditioning and development of smooth muscle 
cells within the constructs. Wall shear stress plays a large role in the organization of 
endothelial cells, as well as their alignment to the direction of flow and maturation on the 
graft [33,41,42]. As the scaffold is stretched with the pulsatile strain, production of 
collagen and elastin is stimulated leading to better remodeling of the decellularized 
vessels [43]. Along with mechanical cues, growth factors may be added to the culture 
medium of the bioreactor to further encourage differentiation of the seeded cells. In 
combination with mechanotransduction, these cues are instrumental in allowing the stem 
cells time to adjust and adapt in the dynamic environment while promoting construct 
remodeling.   
 
2.4.2 Current TEVG Approaches 
Current studies have shown the use of decellularized tissue reseeded with cells to be a 
promising approach. Tillman et al. 2012 showed positive results in an ovine model. 
Decellularized porcine carotid arteries were seeded with endothelial progenitor cells 
followed by preconditioning in a bioreactor for 2 weeks. This was performed prior to 
implantation to adjust grafts to arterial flows [44]. The importance of in-vitro pre-
conditioning was also reported by Kaushal et al. 2010 A gradual increase of shear stress 
(1 dyn/cm2 – 25 dyn/cm2) over 2 days optimized cell retention. Pre-conditioned grafts 
$*!
were implanted into an ovine model to replace a portion of the carotid artery and all EPC-
seeded grafts remained patent up to 130 days after implantation [45]. Many groups 
recognize the importance of pre-conditioning the tissue-engineered grafts but also 
understand there are associated drawbacks. The production and operation of bioreactors 
can be difficult and require extensive training. There can be many components requiring 
sterilization and multiple steps during the process. Schulte et al. 2014 aimed to build an 
all-in-one system that allowed simultaneous seeding, rotation and perfusion of the grafts
[46]. The all in one design is shown in Fig.6. The design fits on a secure base plate that 
can fit into a cell culture incubator. The seeding chamber is capable of rotation for even 
cell distribution and can be connected to the main flow after seeding is achieved. The 
design includes a pump, potentiometer and pulse generator. 
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All-in-one bioreactor build includes 1) seeding device, 2) rotating mixer, 3) media 
reservoir 4) control unit, 5a) roller pump, 5b) potentiometer, 6) pulse generator.  
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The combination of tissue engineered grafts and bioreactor systems presents many 
promising solutions for testing not only grafts, but also medical devices and 
substances. An ultimate goal for systems like this is to reduce the animal model 
burden by performing in-vitro testing in specialized systems.  
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CHAPTER THREE: DEVELOPMENT OF BLOOD VESSEL TISSUE 
ENGINEERING IN VITRO MODEL 
3.1! Rationale
A vascular bioreactor system is necessary to dynamically condition TEVGs as well as to 
recreate physiologically relevant environments. This chapter explores the development of 
a vascular bioreactor to simulate a hyperglycemic environment as well as a hypertensive 
environment.   
Figure 7: Vascular Tissue Engineering Paradigm 
Overview of general approach to producing a patient-tailored vascular graft. 
Beginning with harvesting of carotid artery from a porcine model and 
subsequent decellularization. Autologous cells are isolated and expanded 
before reseeding the vascular graft. The graft is dynamically conditioned in a 
vascular bioreactor prior to implantation into patient. 
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3.2! Vascular Bioreactor for Hyperglycemic Conditioning  
To mimic physiological conditions in vitro, a vascular bioreactor was previously 
designed by lab members Dr. James Chow and Dr. Lee Sierad. The bioreactor was 
designed in SolidWorks and machined by the Clemson Machining and Technical 
Services. 
 
 
Figure 8: Vascular Bioreactor 
Vascular bioreactor developed by James Chow and Lee Sierad. Schematic of 
design shown in SolidWorks and resulting build. 
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This newly designed iteration of the main chamber can accommodate 5 vascular grafts up 
to 4 inches long. Stainless steel “quick” barbed fittings provided a quick through wall 
connector featuring an o-ring seal for superior sterility. An o-ring at the interface of the 
body and the lid also provides a tight seal and increased sterility. A sloped aluminum 
base combined with an air bubble channel grooved into the polycarbonate lid provides 
ease when filling the chamber. The acrylic body of the chamber can be sterilized with 
ethylene oxide gas and provides excellent visualization of the grafts. This bioreactor was 
designed to be constructed quickly while minimizing the risk of contamination. To 
accommodate a wider range of graft sizes, a minimal adjustment was made to the 
previous designs. The stainless steel through-wall fittings were outfitted with connections 
to Leur fittings on one end. This allows for commercially available male Leurs fittings of 
varying inner diameters to connect to the stainless steel fittings. These fittings can be 
matched to the vessel grafts prior to mounting in the bioreactor to ensure appropriate fit.  
 
 
 
 
Figure 9: SolidWorks Modification 
of Through-Wall Fitting 
New design rendered in 
SolidWorks for through-wall 
fittings to allow quick assembly 
and interchangeable Leur fittings 
for better matching of inner 
diameters.  
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The new chamber is connected in a flow loop and flow can be controlled through the use 
of a peristaltic pump. As shown in Fig.10, a closed reservoir directly following the pump 
acts as a pulse dampener to lessen the peristaltic action from the pump. Culture media is 
perfused across the graft byway of a manifold to divert the flow. The media re-enters and 
fills the large chamber to completely bathe the grafts. Media exits the chambers and 
Figure 10: Hyperglycemic Vascular Bioreactor Schematic 
General schematic outlining the flow loop and components of the vascular 
bioreactor used in the hyperglycemic experiments.  
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enters a reservoir where sterile gas transport can take place via a 0.2µm filter cap atop the 
reservoir. The media continues back to the peristaltic pump completing the loop.  
 
3.2.1 Advantages and Drawbacks 
The major advantage of this design as compared to previous iterations is the number of 
samples that can be housed in a single reservoir. With one bioreactor system, 5 samples 
can be run at the same conditions. The main reservoir simplifies assembly much more 
than if the vessels were housed individually. The compact size allows for easy removal 
and transportation during media changes. As well, due to its small size, the system easily 
fits within a standard cell culture incubator. However, this design has its drawbacks. This 
system requires the use of a peristaltic pump. Traditionally, a large multi-head peristaltic 
pump (Cole Parmer) is used. Multiple systems can be attached to the peristaltic pump 
which is convenient to conserve space, however if your conditions require variable flow 
speeds it will require a separate pump and additional space in an incubator. As well this 
design is controlled only through the use of the pump’s internal settings. For experiments 
focused on biochemical cues this does not pose much of an issue, but for increased 
experimentation with biomechanical cues, more sophisticated parameters and controls are 
needed.  
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3.3! Vascular Bioreactor for Hypertensive Conditioning 
 
A partnership was enacted with Aptus Bioreactors, a local bioreactor-development 
company, to improve the vascular bioreactor. Developing design inputs and 
Figure 11: Hypertensive Vascular Bioreactor Schematic 
General schematic outlining the flow loop and components of the vascular 
bioreactor used in the hypertensive experiments.  
 
	 25	
validating various components or assembled portions of the system were my main 
objectives during a 3-month internship in the engineering department. 
Final manufacturing and assembly was coordinated by Aptus Bioreactors and systems 
were leased for the duration of the experiments. The previous hyperglycemic vascular 
bioreactor was outfitted with new controls to have a wider control over the parameters. 
This new iteration would allow us to experiment with various pressures and flows to 
better model physiological conditions. 
 
3.3.1 Bioreactor Additions and Development 
As compared to the previous iteration, the hypertensive bioreactor needed additional 
capabilities. The pressure waveform is a complex parameter that can be affected by 
minute changes in constriction and even tubing compliance [47]. By modifying the 
location and magnitude of constriction, diastolic and systolic pressures can be modulated.  
Peristaltic pumps allow the isolation of the circulating fluid from the pump by the action 
of roller heads directly on the tubing of the flow loop. Addition of a pulse dampener 
following the peristaltic pump acts to reduce the noise introduced by the pump as well as 
to smooth out high and low frequency peaks. The reduction of noise depends on the 
presence and volume of air within the pulse dampener. Glass vessels were designed with 
removable caps to allow adjustment of air levels to optimize the noise reduction as shown 
in Fig.12. Additional compliance chambers were added to aid in the modulation of 
pressures. Three constriction clamps distributed in the system as shown in Fig.11 act as 
the primary control  
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A pinch valve modifies the amplitude of the pressure wave also known as the pulse 
pressure. As seen in Fig.11, these components are now included in the design. However, 
the addition of these components resulted in the need for a system to control and collect 
the data. Using Aptus Vascular Software we could simultaneously monitor flow rate, two 
pressures and modulate the pinch valve.  
 
 
 
 
 
Figure 12: Glass Pulse Dampener
Pulse dampener constructed of glass with removable cap to adjust fluid levels 
and inlet and outlet to connect to flow loop.  
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3.3.2!Fittings Modifications
An upgraded design of the through-wall fittings was implemented. With the increase of 
flow and pressure required by our new final parameters, it is important that the flow from 
manifold to fitting and through the vessel is as seamless as possible. New stainless steel 
fittings were designed by Aptus for a more seamless flow and are used combination with 
the new custom 3D-printed fittings to transition from fitting to the vessel. The new 
fittings can be matched to the diameter of the graft’s lumen, and unlike traditional Leur 
Figure 13: SolidWorks Modification of Through-Wall Fitting 
New through-wall fittings designed by Aptus Biroeactors coupled with attached 
custom 3D-printed fitting. O-rings shown to indicate appropriate operation. 
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style fittings, the new fittings do not have a large constriction of flow. This new design 
allows for a more relevant modeling of flow through the vascular grafts.  
 
3.3.3 Advantages and Drawbacks 
This new iteration of the bioreactor has a few key major improvements. With the addition 
of the constriction clamps, and pinch valve, pressures and flows can be adjusted and 
monitored. The ability to monitor and adjust these parameters provides more relevant 
physiological conditions than the previous iterations. As well, this design is much more 
compact due to the fact that the controlling unit contains the electronic system, all ports 
for cables as well as a peristaltic pump. The included pump is much smaller than 
previously used pumps which allows for an individual pump to be used in each system 
and to still easily fit within a cell culture incubator. There are still some modifications 
that can be done to further improve these systems. The constriction clamps are currently 
manually controlled. These must be loosened during media changes and repositioned 
after. Eventually, electrically controlled constriction clamps would be preferable as they 
could modulate the constriction to modify the pressures automatically.  
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CHAPTER FOUR: HYPERGLYCEMIC BIOREACTOR 
4.1 Rationale and Hypothesis 
Tissue engineered blood vessels are exposed to harsh environments upon implantation in 
diabetic patients. Our aim is to simulate the modification of the TEVG that would occur 
in this pathological environment. We hypothesize that the high glucose environment 
simulated in our in-vitro model will alter the efficacy of differentiation of adipose stem 
cells into targeted vascular cells.  
 
4.2 Materials and Methods 
4.2.1 Vascular Graft Preparation 
Fresh porcine carotid arteries obtained from Animal Technologies, Inc. (Tyler, TX),  
Excess fat was removed from the arteries followed by incubation in 0.1M NaOH solution 
at 37°C for 24 hours. This was followed by extensive rinsing with deionized water until 
the pH of the rinse water dropped to neutral. Scaffolds were stored in sterile 1X PBS. 
This treatment removed cellular epitopes and most of the collagen, leaving vascular 
elastin fibers unaltered. Half of the arterial elastin scaffolds were treated with sterile 0.1% 
PGG in 50nM 4-(2-hydrozyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 5.5, 
containing 20% isopropanol, overnight at room temperature under agitation and protected 
from light. Afterwards, scaffolds were rinsed in sterile 1X PBS. They were then stored in 
sterile 1X PBS containing 1% protease inhibitors and 1% Penicillin-Streptomycin at 4°C. 
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4.2.2 In-vitro Proliferation of HASCs 
Normal culture medium consisted of Dulbecco’s Modified Eagle Medium (DMEM) 
(glucose content 1g/L) with 10% fetal bovine serum and 1% Penicillin-Streptomycin. No 
additional glucose was supplemented. Diabetic media was generated by adding D-(+)- 
Glucose Monohydrate to a concentration of 5.5 g/L. ASCs were plated at a density of 
5000 cells/cm2 and cultured in either control or diabetic media for up to 4 weeks on tissue 
culture plastic.  
 
4.2.3 Vascular Graft Seeding 
Ten vascular grafts (~6- 7cm in length) were prepared for seeding. Barbed Leur fittings 
of varying sizes were matched to the ends of each graft and zip tied to secure the graft. 
The decellularized elastin scaffolds were seeded to both the adventitia and the lumen with 
expanded hASCs to yield a vascular graft.  A total of (3x104/mm2) ASCs were injected 
into the media at varying sites along the scaffold with a 30-gauge syringe needle. Care 
was taken to inject only the tunica media with minimal perforation into the lumen of the 
graft.  Another (3x104/mm2) ASCs were injected into the lumen of the graft. The lumen 
was sealed by capping the attached barbed luers. Vascular grafts were contained in sterile 
T-25 flasks in a cell culture incubator in DMEM, 10% FBS, and 1% antibiotic solution. 
Grafts were manually turned 90° every 4 hours to ensure ASCs adequate covered the 
lumen surface. 
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4.2.4 Bioreactor Conditioning  
Two vascular bioreactors were assembled, under sterile conditions, one serving as a 
control and the other a diabetic model. The diabetic media comprised of DMEM, 10% 
FBS, and 1% antibiotic solution and additional glucose was supplemented to a 
concentration of 5.5 g/L.  Control media was prepared sans additional glucose. Static 
grafts were kept in T-25 flasks to serve as a control.   
 
4.2.5 Histological Analysis 
Cell viability was evaluated using Live/Dead Viability Assay Kit (Life Technologies). A 
small section of the graft was cut from the center. The tissue was stained according to the 
manufacturer procedure. The cross section was sliced and opened to expose the luminal 
side. Sections were imaged with fluorescence microscopy. Small sections from each graft 
were placed in 10% neutral buffered formalin for a minimum of 24 hours then further 
processed in a tissue processor. Cross sections were embedded in paraffin to examine the 
presence of α-SMA, SMM-hc, CD31, VE-cadherin, CCR7, and CD34 by 
immunohistochemistry. 5um sections were rehydrated and antigen retrieval was 
performed by immersing sections for 20 minutes in a 95-100°C solution of 10mM citrate 
buffer (pH 6.0). Next, sections were treated with 0.025% Triton X-100 solution for 10 
min and blocked in 1.5% normal horse serum for 30 min. A 0.3% hydrogen solution in 
0.3% normal horse serum was used to block endogenous peroxidases for 30 min. Directly 
following, primary antibody was applied at room temperature for one hour, followed by 
specific biotinylated secondary antibody (Vector Labs) for 30 min. VECTASTAIN Elite 
ABC Reagent, R.T.U. was applied, followed by the DAB Peroxidase Substrate Kit. For a 
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negative staining control, the primary antibody was omitted and segments stained only 
with the secondary. Sections were counterstained with hematoxylin before mounting. To 
visualize, digital images were obtained at various magnifications (100X to 200X) on a 
Zeiss Axiovert 40CFL microscope using AxioVision Release 4.6.3 digital imaging 
software (Carl Zeiss MicroImaging, Inc. Thornwood, NY). 
  
&&!
4.3! Results  
4.3.1!In-vitro Conditioning  
Vascular grafts (n=5 per bioreactor) were mounted into the respective reservoir by 
attaching the end of the Leur fitting in the main chamber. A Cole Parmer peristaltic pump 
perfused media at a rate of 1 mL/min through the lumen of the graft. Culture media also 
filled the large reservoir to completely envelop the grafts. Grafts were maintained in the 
dynamic environment for up to 2 weeks in a cell culture incubator at 37°C. 0.2µm filter 
caps on the lids of the media reservoir allowed for sterile gas transport. 
 
 
 
 Figure 14: Vascular Bioreactor Diagram 
Overview of conditions for each vascular bioreactor. Control conditions with 
normal media, and the other rendered diabetic condition with high glucose 
media.  
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4.3.2!Live/Dead Staining
Minimal live cells were observed in the static conditions as compared to the vascular 
grafts conditioned in the dynamic environment.  Alignment of live cells in the direction 
of media flow was observed in both conditions. However, the alignment was more 
pronounced in the control conditions.   
Figure 15: Live/Dead Stain of Lumen of Vascular Constructs 
Calcein AM to indicate live cells and ethidium homodimer to indicate dead 
cells in control and diabetic dynamic conditions and statically cultured 
vascular grafts. Stained on lumen (en face). Green = Live. Red = Dead. 
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4.3.3 Histological Analysis 
Upon examination of time zero grafts (incubation time approximately 16 hours post-
seeding), hASCs were seen in boluses in the media of the grafts. Along the internal 
elastic lamina, a monolayer of cells was detected. When compared to the grafts after 2 
weeks of conditioning, the bolus was less pronounced. The residing cells appeared to 
have migrated from the injection site to adjacent areas in the media. Similar results held 
true when examining the lumen: fewer cells remained. a-sma was noted to be present at 
each interval; time zero, up to 2 weeks in both the normal conditions as well as dynamic. 
A greater presence of a-sma was noted at time zero due to the more pronounced bolus. 
Elastin fibers of the matrix exhibited pseudo-positive staining for SMM-hc expression. 
Expression of VE-cadherin was seen at time zero in the cell bolus, as well as after 2-week 
dynamic culture VE Cadherin was seen along the lumen as well. Expression of CD31 by 
the cells remained largely absent at time zero. However, after conditioning, expression of 
the marker was noted on the adventitia of the graft as opposed to the lumen. The effect of 
the diabetic conditions is unclear. There was no noticeable shift of hASCs towards the 
vascular phenotypes. But it is clear that the mechanical cues and stresses the vascular 
bioreactor places on these grafts modulates the constructs cell retention ability and 
migration.  
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Figure 16: Immunohistochemistry of Vascular Constructs
IHC of vascular constructs at (left column) 2-week post control bioreactor 
conditions, (middle column) 2-week post diabetic bioreactor, and (right 
column) static control conditions stained for CCR7, CD31, VE-Cadherin, "-
SMA, and SMM-hc. Brown = Positive. Purple = Nuclei. 
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4.4 Discussion/Conclusion 
Our definition of diabetic in the context of this experiment is a loose term. We focus 
specifically on the role of hyperglycemia as seen in diabetic patients. We focused on the 
effects a high glucose concentration has on stem cell differentiation and viability in 3D. 
In this native physiological condition with relevant mechanical forces it was our aim to 
determine if the high glucose environment would affect the fate of our vascular grafts. 
Our objective was to scrutinize stem cell differentiation in 3D to determine optimum 
vascular graft development. The forces and stresses exhibited by bioreactors have been 
shown to induce differentiation of stem cells into vascular phenotypes. In our studies, we 
observed the presence of VE-cadherin as well as both SMC markers staining positive 
through the grafts. This was true despite a diabetic or normal conditions. The effects of 
the shear flow and mechanical stresses seem to affect the grafts in a greater manner than 
the diabetic conditions, potentially overshadowing any large effects due to the 
hyperglycemic environment. The alignment of live cells in the direction of media flow 
was observed in both conditions, however, the alignment was more pronounced in the 
control conditions.   
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CHAPTER FIVE: HYPERTENSIVE BIOREACTOR 
5.1 Rationale 
Tissue engineered blood vessels are exposed to harsh environments upon implantation in 
diabetic patients. Our aim is to simulate the modification of the TEVG that would occur 
in this pathological environment. We hypothesize that the hypertensive environment 
simulated in our in-vitro model will induce alterations in the structure of our TEVGs.  
5.2 Materials/Methods 
5.2.1 Vascular Graft Preparation 
Frozen carotid arteries were obtained from Animal Technologies, Inc. (Tyler, TX), and 
thawed at 4°C over 24 hours. Excess fat was removed from the arteries followed by 
incubation in 0.1M NaOH solution at 37°C for 24 hours. This was followed by extensive 
rinsing with deionized water until the pH of the rinse water dropped to neutral. Scaffolds 
were stored in sterile 1X PBS with 1% Penicillin-Streptomycin. This treatment removed 
cellular epitopes and most of the collagen, leaving vascular elastin fibers unaltered. 
5.2.2 In-vitro Proliferation and Differentiation of HASCs 
Human adipose stem cells (hASCs) Fisher Scientific, Life Technologies) were obtained 
and expanded in StemPro Human AdiposeDerived Stem Cell Kit with 1% antibiotic 
solution (#30-004-CI, Corning – Cellgro). hASC’s were cultured at sub confluent 
conditions on tissue culture plastic. For differentiation of hASCs to endothelial-like cells, 
ASCs were cultured for up to 6 weeks in EC differentiation media comprised of DMEM, 
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2% FBS, and 1% antibiotic solution. After sufficient cell numbers were reached, cell 
media was supplemented with 0.5 ng/mL vascular endothelial growth factor (VEGF, 
#100- 20B, PeproTech Inc) and 20 ng/mL insulin-like growth factor-1 (IGF-1, #AF-100-
11, PeproTech Inc) at the time of each media change. Similarly, for differentiation of 
hASCs to fibroblast-like cells, cells were cultured for up to 6 weeks in fibroblast 
differentiation media comprised of DMEM, 5% FBS, and 1% antibiotic solution. The 
culture media was supplemented with 5ng/mL transforming growth factor beta-1 (TGF-
β1, #100-21C, PeproTech Inc.) at the time of each media change. 
5.2.3 Fibrin Gel Fabrication 
Fibrinogen (#F8630, Sigma Aldrich) was reconstituted into 1X PBS and slowly dissolved 
at 37°C overnight before sterilization through a 0.2µm filter. Thrombin (#T7009, Sigma 
Aldrich) and CaCl2(#BP510-100, Fisher Biotech) were combined and filtered to render 
sterile. Final concentration of consisted of 0.5U/mL thrombin, 4mg/mL fibrinogen, and 
2mM CaCl2. 
5.2.4 Vascular Graft Seeding 
Grafts were cut into 4-5 cm sections and fittings were chosen to closely match inner 
diameter to the lumen of the artery. O-rings were used to securely attach the graft to the 
fitting. The pre-differentiated endothelial cells were re-suspended in the thrombin 
calcium mixture. Immediately before injection, the thrombin mixture was combined with 
the fibrinogen to initiate the formation of the fibrin gel. Silicone plugs were used to cap 
one side of the graft and a total of (2.6x104/mm2)  pre-differentiated endthoelial HASCs 
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were injected into the lumen of the artery. The remaining end of the artery was plugged 
with a silicone plug to prevent leakage of the cell mixture. This was repeated for each 
subsequent graft for each bioreactor, including a graft to be kept as a static control. Each 
vessel was placed in a sterile 50mL conical with culture medium to prevent the grafts 
from drying out. Each conical was then securely attached to a rotating device and set to 
rotate 0.5 revolution per minute for 1 second and to hold in between rotations for 15 
seconds. This procedure continued over 2 hours to ensure adequate cell attachment and 
even fibrin gel distribution across the lumen. Following this, (1x104/mm2) pre-
differentiated fibroblast HASCs were drop seeded onto the adventitia of each graft. To 
minimize cell loss, silicone tube acted as channels for the  
Figure 17: Seeding of Vascular Graft 
Silicone tubing used as a trough during drop seeding of pre-differentiated 
Fibroblast HASCs onto the vascular graft. 
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grafts to rest in and catch any run-off. Cells were allowed to attach for 1 hour before 
rotation was resumed and additional culture medium added to the grafts in the conical. 
5.2.5 Bioreactor Conditioning 
Following seeding, each bioreactor was assembled in a sterile hood. The primary method 
of sterilization was steam sterilization save the acrylic chamber and hand tools that 
required sterilization by ethylene oxide gas. Culture medium composed of DMEM, 10% 
FBS, and 1% antibiotic solution was used to fill each bioreactor. 5 vascular grafts were 
mounted into each bioreactor and sealed. The system was placed in a cell culture 
incubator to maintain appropriate temperatures and gas levels. Additional Penicillin-
Streptomycin was added every 3-4 days and the culture medium replaced every 7 days. 
Grafts were housed for 4 weeks before removal for analyses. 
5.2.6 Mechanical Testing 
MTS Synergie 100 Single Column Universal Test Machine was used to determine the 
radial elastic modulus of the conditioned vascular grafts. 1cm sections from the 
bioreactor-conditioned vascular grafts were cut opened as depicted in the Fig.17 and 
flattened to yield a 1 cm x 3 cm rectangular sample shape. The loading blocks of the 
machine were lined with sandpaper and a portion of each end of the artery was clamped 
to prevent slippage. Final elastic modulus was determined for n=4 samples.  
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Samples of the bioreactor-conditioned vascular grafts are cut and 
oriented as shown in the diagram to the left. Top and bottom ends are 
secured with sandpaper in the loading blocks as force is applied. 
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5.2.7 Histological Analysis 
Cell viability was evaluated using Live/Dead Viability Assay Kit (Life Technologies). A 
small section of the graft was cut from the mid-section of the graft. The tissue was 
stained according to the manufacturer procedure. The cross section was sliced and 
opened to expose the luminal side. Sections were imaged with fluorescence microscopy. 
Small sections from each graft were placed in 10% neutral buffered formalin for a 
minimum of 24 hours then further processed in a tissue processor. Processed tissues were 
embedded in paraffin and at 5um sections were stained with Hematoxylin and Eosin 
(H&E) and Masson’s Trichrome according to manufacturer protocols (Poly Scientific 
R&D Corp) for a general overview of morphology. 
5.3 Results  
5.3.1 In-vitro Bioreactor Conditioning 
Following seeding, each bioreactor was assembled in a sterile hood. The main chamber 
was filled with culture medium before attaching each graft. Grafts were secured to the 
stainless steel through-wall fittings with the protection of an O-ring securing each fitting. 
Following the securement of the final graft, the main chamber was sealed with the lid and 
an o-ring and bolted into place. Culture medium was slowly added to fill the entire 
bioreactor before sealing the entire flow loop. Each bioreactor was attached to a separate 
Aptus vascular system. The system served to establish separate pressures for each 
condition, to control the pump and monitor. Care was taken to ensure cell attachment by 
slowly ramping up the conditions of the bioreactor as seen in Fig.18. The internal pump 
was set to a flow rate of 3% power of the pump which translates to 10 ml/min. Over the 
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course of a week the intervals of the pinch valve were slowly decreased to a final pace of 
500ms open, 300ms closed. Upon ramping up the pressure in the second week, the flow 
of the pump was increased to 5%, or 18 ml/min in order to achieve the desired pressures. 
Over the course of a week pressures in the normal and hypertensive bioreactor were 
ramped to a final pressure of 120/85 and 140/90 respectively. The goal was to run the 
bioreactor for approximately 2 weeks at the final physiologically relevant pressures to 
provide enough exposure time at the maximum pressures.  
 
 
Figure 19: Bioreactor Conditioning Regime for Ramp-Up 
To ensure adequate time for cell to adjust to the pressures and flow, care was 
taken to slowly ramp up conditions in the bioreactor.  
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Each bioreactor, as shown in Fig.17, connected to a separate computer controlled system 
for greater control over flow and pressures to apply correct pressures and flow for each 
condition. As shown, this new compact system with internal peristaltic pump easily fits 
two separate setups into a standard cell culture hood. Each system was controlled by a
separate computer running Aptus Vascular Bioreactor Software. Each system possessed 
the capability to simultaneously monitor 2 pressure transducers, one flow meter and 
could be programmed to modulated a pinch valve and a peristaltic pump.  
Figure 20: Mounting 
Seeded Vascular Graft 
into Bioreactor  
Five vascular grafts 
mounted into assembled 
bioreactor and sealed. 
Culture medium fills 
chamber and reservoir to 
bathe the grafts. 
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Aptus Vascular Software was used to control the peristaltic pump and the pinch valve. 
Pump speed was set as a percentage of the voltage of the pump which results in a linear 
increase in speed of the roller heads of the pump. The flow in the bioreactor was 
monitored with a flow meter and could be displayed on the software. The two transducers 
provided a reading to output as shown in Fig.21. Displays of the pressure profiles after 
completion of the ramp up cycle are shown of both the normal and hypertensive 
conditions. 
Figure 21: Cell Culture 
Incubator Housing Two 
Bioreactors  
Two complete Aptus 
bioreactor systems easily fit 
enclosed in a cell culture 
incubator. Controlling units 
are connected by feeding wires 
through the incubator. 
'*!
 
 
 
 
 
Figure 22: Pressure Profile of Bioreactors 
Snapshot of Aptus Vascular Bioreactor Software shows main controlling 
display (A) to set peristaltic pump speed and pinch valve delay. Display of the 
normal conditions (B) and hypertensive conditions (C) is shown at the end of 
the ramp up cycle.
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5.3.2!Differentiation of HASCs to Vascular Phenotypes 
Figure 23: Immunocytochemistry and Immunofluorescence of Pre-Differentiated HASCs 
Immunocytochemistry (A) results shown for endothelial-cell (EC) differentiated HASCs. 
CD-31 and Von Willebrands’s Factor (vWF) were stained for. (brown = positive. 
Immunofluorescence (B) performed on fibroblast (FB) differentiated HASCs. Cells were 
stained for markers (HSP-47) and Vimentin. (green = positive, images taken at 10X 
magnification) 
',!
HASCs were pre-differentiated in 2D culture prior to seeding on prepared vascular 
grafts. Immunocytochemistry and immunofluorescence was performed to investigate the 
potential of HASCs to differentiate to vascular phenotypes. The results of the staining is 
shown in Fig.22 
 
5.3.3!Live/Dead Staining  
Live/Dead was performed on seeded vascular grafts kept at static conditions during the 
operation of the bioreactors. Cells were still present in both the lumen as well as the 
adventitia, however cells death was also seen in both locations as well. Some spreading 
of the cells was noticed in the adventitia however minimal was noticed with the EC 
differentiated cells. 
Figure 24: Live/Dead Evaluation of Static Vascular Graft 
Live/Dead images of static vascular grafts. Grafts were cut and lain flat to obtain 
images from the luminal side and the adventitial side. 
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Live/Dead staining of the vascular grafts following removal from the bioreactor 
confirmed presence of cells in both the normal and hypertensive vessels. Cells were 
found in both the lumen and adventitia, however cell presence was lessened as compared
to time zero and static conditions. The cells in both conditions and in both the adventitia 
and lumen appeared to be elongated in the direction of the flow.  
 
 
 
Figure 25: Live/Dead Evaluation of Bioreactor-Conditioned Vascular Grafts 
Live/Dead images of bioreactor-conditioned vascular grafts. Grafts were cut and lain flat to 
obtain images from the luminal side (top row) and the adventitia (bottom row) from both the 
normal group and hypertensive bioreactor conditions. 
	 51	
5.3.4 Histological Analyses  
H&E staining was performed on the of the grafts following bioreactor conditioning as 
shown in Fig.24. Some cells could be seen lining the endothelium, but more cells may be 
present on further sections. Images revealed general maintenance of integrity of the 
tissue. However, in the hypertensive group, the outer lamellae fibers showed signs of 
fraying. Masson’s Trichrome staining was performed to investigate the relative levels of 
collagen and elastin. The images from the hypertensive group visually appeared to 
possess a greater presence of collagen as shown in Fig.25 as compared to the normal 
group.  
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Figure 26: Hematoxylin and Eosin staining of Bioreactor-Conditioned Vascular Grafts 
H&E staining of both the normal (left two columns) and hypertensive bioreactor-
conditioned grafts (right two columns). (pink=ECM purple = nuclei) 
(&!
 
 
 
 
 
Figure 27: Masson’s Trichrome Staining of Bioreactor-Conditioned Vascular 
Grafts 
Masson’s trichrome staining of both the normal (left two columns) and hypertensive 
bioreactor-conditioned grafts (right two columns). (brown=elastin, blue = collagen) 
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5.3.5!Collagen Quantification 
The images captured from the Masson’s staining were used to quantify the percentage of 
collagen content. Images were processed using ImageJ and the results as seen in Fig.26 
show a significant increase between the normal and hypertensive bioreactor group.  
 
 
 
 
 
 
 
Figure 28: Collagen Content Quantification of Bioreactor-Conditioned Vascular 
Grafts 
Collagen content was determined by quantifying the percentage of total area of 
collagen to total extracellular matrix composition. Images were quantified in ImageJ 
by color threshold determination. (n=7)  
*indicates statistical significance 
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5.3.6!MTS Quantification 
After 4 weeks conditioning, grafts underwent unidirectional mechanical testing to 
determine the elastic modulus of the conditioned grafts. As seen in Fig.27, the 
hypertensive grafts had a significantly higher modulus as compared to the grafts in the 
normal group. 
 
 
 
 
 
 
 
Figure 29: Elastic Moduli of Bioreactor-Conditioned Vascular Grafts 
Elastic modulus was determined for each group, normal and hypertensive grafts. 
(n=4) 
*indicates statistical significance 
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5.4 Discussion/Conclusion 
Our development of the newly outfitted bioreactor performed well with new 
modifications, was easily sterilized, and its compact nature was beneficial as two 
simultaneous systems needed to be housed in one cell culture unit. The new Aptus 
Bioreactors units were user-friendly, easy to assemble and greatly simplified the task of 
monitoring the data from multiple sensors. During conditioning, the distal portion of the 
grafts, which were thinner by nature were prone to slits forming from the pressures. It is 
possible this is due to the pressures alone, however it is possible there was some damage 
done to the grafts when mounting that could have exacerbated the tearing. Because of this 
the profile of the pressures had to be modulated in as a best a way to maintain appropriate 
systolic and diastolic pressures. The wave forms suffered from the tears in the arteries, 
but pressures were able to be maintained. 
Live/Dead analyses of the grafts after conditioning showed cell retention in both the 
adventitial and luminal face. When compared to the static control, a seeded graft not 
subjected to dynamic conditioning, there was less cell retention. The static controls 
showed dead cells on the grafts, however with the dynamic conditioned grafts, dead cells 
were not located as they were likely removed by the shear of the flow after detaching. It 
was noted that the dynamic grafts showed spreading of cells, specifically on the luminal 
side, whereas the static samples had random orientation and no specified spreading or 
alignment. This finding agrees with the previous bioreactor as well as many groups using 
similar systems. [47] 
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It was noticed in our studies that the subjection of our TEVGs to the hypertensive 
environment induced a pathological stiffening. This is likely due to the over presence of 
collagen in the extracellular matrix. Indeed, this result was qualitatively visualized with 
Masson’s staining of sections. Collagen seemed to increase significantly in the 
hypertensive group and this finding agreed with ImageJ quantification of the images. 
Color thresholding separation showed a significant increase in hypertensive samples with 
collagen comprising approximately half the extracellular matrix of the grafts. The 
detection method used with ImageJ can be used to detect the dominant color, however if 
tissues lie on top of each other, quantification may not be as precise. Further analysis may 
be needed for conclusive evidence. However, this response of increased collagen 
production is not shocking, as it has been shown that dynamic conditioning of vascular 
grafts leads to an increased collagen production and fiber density. ECM is produced by 
the cells of the vascular matrix and indeed, studies have shown that increased 
circumferential stretch leads to an increase of extracellular matrix production [48]. As 
well, the elastic modulus of the grafts in the hypertensive group was shown to be 
significantly higher than the normal pressures group. Although less cells remained than 
initially seeded, cells were still found to be present on both the adventitia and lumen of 
the grafts. Cells were conditioned on the graft for 2 weeks at lower conditions before a 
slow ramp up, providing time for deposition of collagen by the attached cells. It was also 
noticed that the lamellae of the elastin fiber of the hypertensive groups seemed frayed and 
degraded. This has been shown to be a result of elevated levels of pressure and flow.  
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Based on these results, we believe the systematic increase of the pressure within the 
bioreactor is providing mechanical cues to the vascular graft resulting in alterations to the 
matrix as expected in a similar physiological environment.  
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CHAPTER SIX: FINAL OVERALL CONCLUSIONS 
6.1 Conclusions 
We have developed an in-vitro vascular graft bioreactor to be used in the conditioning 
and testing of tissue-engineered vascular grafts. Additions to the system now allow a 
variety of parameters to better model the pathological environment these grafts would 
eventually be subjected to in-vivo. We have shown our bioreactor can elicit a typical 
response of the vascular grafts as seen in a hyperglycemic and hypertensive environment. 
These results are promising as the use of the in-vitro model can reduce the burden of 
animal models through testing in a simulated environment.   
6.2 Future Directions 
In these experiments we focused on the hyperglycemic and hypertensive conditions 
separately with each iteration of the vascular bioreactor. However, hyperinsulinemia and 
hyperlipidemia are metabolic conditions associated with diabetes. For future in vitro 
studies, a combinatory effect should be investigated. Insulin and free fatty acids should 
be added to the media to for a more representative view of the effect of biochemical cues 
on the TEVG. As well, this should be investigated in combination with the increased 
pressures to better model the mechanical effects a hypertensive environment has on the 
grafts. Finally, for further in vivo characterization of the effect diabetes has on our tissue 
engineered vascular grafts, use of a diabetic animal model for a more complete picture of 
how the grafts are affected would be necessary. 
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